Diogo Patrícia, Correia Gil, Martins João B, Soares Rui, Palma Paulo J, Santos João Miguel, Gonçalves Teresa
Institute of Endodontics, Faculty of Medicine, University of Coimbra, 3000-075 Coimbra, Portugal.
Medical Microbiology Research Group, CNC-Center for Neurosciences and Cell Biology, 3004-504 Coimbra, Portugal.
Vaccines (Basel). 2022 Apr 13;10(4):602. doi: 10.3390/vaccines10040602.
The ChAdOx1 nCoV-19 vector vaccine (Vaxzevria, AstraZeneca, Cambridge, UK) was developed at Oxford University and is considered safe for the administration in lactating mothers. Nevertheless, as a novel vaccine, there are gaps in the knowledge regarding possible adverse events in breastfeeding infants of vaccinated mothers. This case report provides first-time data on a possible delayed, cutaneous, adverse reaction in a breastfed, 16-month-old female infant after the first administration of the AstraZeneca vaccine to her 33-year-old mother. Even though, no clinical adverse effects were observed in the mother, her daughter had a 2-day rash in the lower extremities and face. The infant's cutaneous rashes might be a coincidental event. However, all skin lesions were analogous to previous descriptions and photographs of dermatologic reactions, which resolved spontaneously with no medical intervention, in people who had been vaccinated with other COVID-19 vaccines. Our aim is that this short report contributes to the enhancement of parental awareness about the possibility of similar skin rashes in breastfed children when the mothers receive a vaccination and the importance of reporting those adverse reactions to the competent authorities.
ChAdOx1 nCoV-19载体疫苗（Vaxzevria，阿斯利康公司，英国剑桥）由牛津大学研发，被认为对哺乳期母亲接种是安全的。然而，作为一种新型疫苗，对于接种疫苗的母亲所哺乳婴儿可能出现的不良事件，我们的认知还存在空白。本病例报告首次提供了数据，显示一名16个月大的母乳喂养女婴，在其33岁的母亲首次接种阿斯利康疫苗后，可能出现了延迟性皮肤不良反应。尽管母亲未观察到临床不良反应，但她的女儿下肢和面部出现了为期两天的皮疹。婴儿的皮肤皮疹可能是偶发事件。然而，所有皮肤病变均与接种其他新冠疫苗者的皮肤反应先前描述及照片相似，未经医疗干预即自行消退。我们的目的是，这份简短报告有助于提高父母的意识，让他们了解母亲接种疫苗时母乳喂养儿童出现类似皮疹的可能性，以及向主管当局报告这些不良反应的重要性。
